Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141294 | 0.88 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1141310 | 0.86 | RXRA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1141263 | 0.83 | RXRA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1141755 | 0.81 | RXRA (0.43) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1141583 | 0.81 | DGAT1 (0.34) | CYP4F2CYP4A11ATRDGAT1NPC1 | |
| SCHEMBL17588940 | 0.79 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL26920565 | 0.79 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29734718 | 0.79 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL138511 | 0.79 | RXRA (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL4116261 | 0.78 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468729-B1 | Novel indazole derivative | UBE INDUSTRIES (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-1679308-B1 | NOVEL INDAZOLE DERIVATIVE | UBE INDUSTRIES (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8252945-B2 | Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient | UBE INDUSTRIES, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1870099-A1 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL COMPRISING INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | Ube Industries, Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | CYP4F2 3200/4885CYP4A11 1459/4885RXRA 1731/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | CYP4F2 1461/4885CYP4A11 254/4885RXRA 1666/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | CYP4F2 3323/4885CYP4A11 1558/4885RXRA 1902/4885 |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | GRIK3, ALDH1A2, GRIN3A | CYP4F2 4660/4885CYP4A11 4821/4885RXRA 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.